Genekam Biotechnology AG has developed a number of solutions and molecules, which can be used to inhibit the Ebola infections in order to create new therapies. These molecules can be sourced from us and laboratories around the world can conduct the research studies e.g. preclinical and clinical to demostrate that these molecules can inhibit the Ebola viruses. Not only this, we are trying to develop more molecules to inhibit the Middle east Respiratory syndrome viruses infections (SARS virus), dengue viruses, Influenza viruses as well as animal viruses like Foot and mouth disease etc.
Genekam has developed two different systems to create the molecules, which have potential to be used as therapies one day:
These molecules offer the new chances to many laboratories around the world to conduct the research in the field of therapies. Much of research work can be conducted and published as Master or Ph.D. thesis or reseach paper. These molecules are being offered to any laboratory around the world to conduct world class research in the field of therapeutic or inhibiting the viral pathogens. The above said molecules can be used to inhibit the viruses in human and animals i.e. if they have potential to be used for human and veterinary medicine one day.
2.1 Genekam-T-001 A molecule against Ebola virus | 10 reactions | call |
2.2 Genekam-T-002 A molecule against Ebola virus | 10 reactions | call |
2.3 Genekam-T-003 A molecule against Ebola virus | 10 reactions | call |
2.4 Genekam-T-004 A molecule against Ebola virus | 10 reactions | call |
2.5 Genekam-T-005 A molecule against Ebola virus | 10 reactions | call |
2.6 Genekam-T-006 A molecule against Ebola virus | 10 reactions | call |
2.7 Genekam-T-007 A molecule against Ebola virus | 10 reactions | call |
2.8 Genekam-T-008 A molecule against MERS virus | 10 reactions | call (available within 2 weeks) |
2.9 Genekam-T-009 A molecule against MERS virus | 10 reactions | call (available within 2 weeks) |
2.10 Genekam-T-010 A molecule against MERS virus | 10 reactions | call (available within 2-3 weeks) |
2.11 Genekam-T-011 A molecule against Foot and mouth disease (FMD) | 10 reactions | call (available 4-8 weeks or later) |
Please work with us for these molecules. If there will be successful with the research of such molecules, applications of these molecules may change the ways to generate the new therapies in future.
Therapeutic Molecules | Stage 1 (Development) | Stage 2 (In vitro studies) | |
TM1 | Activin A receptor II | ||
TM2 | Dengue Virus 2 -Version 1 | passed | |
TM3 | Dengue Virus 2 -Version 2 | passed | |
TM4 | Dengue Virus 2 -Version 3 | passed | |
TM5 | Dengue Virus 2 -Version 4 | passed | |
TM6 | Ebolavirus – Version 1 | passed | |
TM7 | Ebolavirus -Version 2 | passed | |
TM8 | Epstein Barr Virus | passed | |
TM9 | H5N1 Neuraminidase | passed | |
TM10 | H5N1 Matrix | passed | |
TM11 | H5N1 Hemagglutinin | passed | |
TM12 | Human Polyomavirus -Version 1 | passed | |
TM13 | Human Polyomavirus -Version 2 | passed | |
TM14 | Human Papillomavirus 16 | passed | |
TM15 | Human Papillomavirus 5 | passed | |
TM16 | Human CD38 -Version 1 | passed | |
TM17 | Human CD38 -Version 2 | passed | |
TM18 | Human CD27 | passed | |
TM19 | Human CD19 | passed | |
TM20 | Japanese Encephalitis Virus | passed | |
TM21 | Middle East Respiratory Syndrom (MERS | passed | |
Z103 | Porphyromonas gingivalis | passed | |
TM22 | Rabies (Lyssavirus rabies) | passed | |
TM23 | Rift Valley Fever Virus | passed | |
TM24 | TNF alfa | passed | |
TM21 | Wuhan Corona | passed | |
Z101, Z102 | Zika Virus | passed | passed |